10-Q: Bluejay Diagnostics Faces Cash Crunch, Seeks $20M+

Bluejay Diagnostics reports a net loss of $1.92 million for Q1 2026 and highlights substantial doubt about its ability to continue as a going concern, requiring at least $20 million in new capital by the end of 2027.

Summary

• Bluejay Diagnostics reported a net loss of $1,919,241 for the first quarter ended March 31, 2026, compared to a net loss of $1,864,435 for the same period in 2025.
• The company's cash and cash equivalents decreased to $3,684,457 as of March 31, 2026, from $5,164,875 as of December 31, 2025.
• Operating expenses for the quarter were $1,938,831, a slight increase from $1,888,917 in the prior year's quarter.
• The company estimates its current cash resources will only fund operations through the third quarter of 2026.
• Bluejay Diagnostics plans to raise at least $20 million in capital by the end of fiscal year 2027 to fund its operations, clinical trials, and FDA submission efforts.
• The company is progressing with its Symphony IL-6 test development, with patient enrollment in the SYMON-II clinical study nearing completion and aiming for an FDA 510(k) submission in the first half of 2027.
• A 1-for-4 reverse stock split was effective on January 29, 2026.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing negatively due to the significant net loss, the substantial doubt regarding the company's ability to continue as a going concern, and the urgent need for substantial capital, which overshadows the incremental progress in clinical studies.

Positives

• Patient enrollment in the SYMON-II clinical study is progressing, with approximately 680 out of a target of 750 patients enrolled as of May 5, 2026.
• The company has successfully resolved technical issues related to Symphony cartridge manufacturing with its contract manufacturer, Sanyoseiko.
• The SYMON-I pilot study suggested that IL-6 levels may predict patient mortality in sepsis patients, potentially highlighting the value of the Symphony IL-6 test.
• The company completed a $125,000 private placement in March 2026, with directors and officers participating.

Negatives

• The company has an accumulated deficit of $43,436,508 as of March 31, 2026.
• Net cash used in operating activities increased to $1,589,200 in Q1 2026 from $1,184,857 in Q1 2025.
• The company's current cash resources are estimated to be sufficient only through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern.
• The company expects to need to raise at least $20 million by the end of fiscal year 2027, and there is no assurance that this capital will be available.
• The company has not yet received regulatory clearance for its Symphony platform from the FDA.
• The royalty rate payable to Toray Industries for cartridge sales was reduced from 15% to 7.5% under the new license agreement, but no sales have occurred yet.
• The company incurred $787,755 in offering costs for the October 2025 private placement, including a $360,000 financial advisory fee.

Risks

• The company's ability to continue as a going concern is dependent on obtaining significant additional financing.
• Failure to obtain necessary FDA regulatory authorization for Symphony could prevent or delay market launch.
• Clinical studies may not demonstrate sufficient safety and effectiveness of the Symphony IL-6 test, potentially delaying or preventing regulatory clearance.
• The company relies on its contract manufacturer, Sanyoseiko, for the production of analyzers and cartridges, and any supply interruptions could delay FDA submissions.
• The company faces risks associated with rapid technological change and competition from larger biotechnology companies.
• The company may need to relinquish valuable rights to its technologies or future revenue streams if it raises additional funds through collaborations or strategic alliances.
• If the company cannot obtain needed financing, it may be forced to delay or reduce the scope of its research, development, commercialization efforts, or manufacturing commitments.

Future Outlook

The company expects to need to raise at least $20 million in capital between the date of this filing and the end of fiscal year 2027. The current plan is to begin testing samples for the SYMON-II clinical trial by the end of 2026, submit a 510(k) regulatory application to the FDA in the first half of 2027, and achieve FDA clearance thereafter. Future research and development expenses will focus on clinical trial programs, technology transfer, and manufacturing improvements. General and administrative expenses are expected to be monitored and pared down to optimize operational alignment.

Management Comments

• "The Company expects that it will not be in position to submit a 510(k) regulatory application to the FDA for Symphony until at least 2027, if it is even able to generate sufficient clinical trial results to support such a submission."
• "If the Company fails to obtain sufficient future financing, its clinical trials and targeted FDA submission timeline could be delayed, and it could be forced to abandon such activities entirely and cease operations, with the possible loss of such properties or assets."
• "The Company estimates cash resources will be sufficient to fund its operations through the third quarter of 2026."
• "We expect to monitor and continue to pare our general and administrative spend, as necessary, to optimize operational alignment."

Industry Context

StockSavvy.ai notes that Bluejay Diagnostics operates in the highly competitive medical diagnostics sector, focusing on critical care settings like sepsis. The company's progress towards FDA clearance for its Symphony platform, particularly the IL-6 test, is crucial. The current financial situation, with a significant need for capital and a short cash runway, is a major concern that overshadows the potential clinical advancements.

Comparison to Industry Standards

• The company's net loss of $1.92 million for the quarter is substantial for a company at this stage of development, especially when compared to established diagnostic companies with approved products generating significant revenue.
• The need to raise $20 million by 2027 is a common requirement for pre-revenue diagnostic companies seeking FDA approval, but the short cash runway (through Q3 2026) indicates a pressing need for immediate funding.
• The SYMON-I study's findings on IL-6 as a predictor of mortality in sepsis patients align with ongoing research in the field, where biomarkers for early sepsis detection and risk stratification are highly sought after.

Legal Proceedings

• The company is not currently involved in any legal proceedings.

Related Party Transactions

• In March 2026, the company sold 62,500 shares of common stock for $125,000 to Neil Dey (CEO), Donald Chase (Chairman), Svetlana Dey, Douglas Wurth, and Fred Zeidman (all directors).
• The company had an agreement with NanoHybrids, Inc. (an entity formerly led by a former CTO) for R&D staff and lab facility use, which was terminated in May 2025. The company paid $50,000 to Nanohybrids and reimbursed up to $30,000 in legal fees as part of the termination.

Stakeholder Impact

• Shareholders: The company's going concern issues and need for significant capital raise could lead to dilution or a complete loss of investment if liquidation occurs.
• Employees: Continued operations and potential future success depend on securing funding; job security may be impacted by financial distress.
• Creditors: The company's ability to meet its liabilities is uncertain, posing a risk to creditors.
• Suppliers: The company's financial instability could affect its ability to pay suppliers on time.

Next Steps

• Complete patient enrollment in the SYMON-II clinical study in the summer of 2026.
• Manufacture and verify Symphony cartridges to meet FDA requirements during 2026.
• Begin testing of samples collected as part of the SYMON-II clinical trial by the end of 2026.
• Submit a 510(k) regulatory application to the FDA during the first half of 2027.
• Seek FDA clearance thereafter.
• Raise at least $20 million in capital by the end of fiscal year 2027.
• Explore potential pathways to raise additional material capital.

Key Dates

Recommendation

While the company is making progress on its clinical trials and manufacturing, the significant going concern risk and the urgent need for substantial capital raise are major deterrents. The current cash runway is extremely short, and failure to secure funding could lead to liquidation. Investors should hold and await further developments on the capital raise and FDA submission progress, while acknowledging the high risk.

Keywords

Bluejay Diagnostics, Form 10-Q, Sepsis, Symphony platform, IL-6 test, FDA clearance, Clinical trials, Capital raise, Going concern, Medical diagnostics